Regulatory10 Aug 2026, 02:59 pm
Akums Drugs IPO Proceeds Utilization Report Filed
AI Summary
Akums Drugs and Pharmaceuticals Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, prepared by CRISIL Ratings Limited. The report details the utilization of proceeds from the company's Initial Public Offer (IPO). As per the report, there are no deviations from the objects stated in the prospectus. The total gross proceeds from the IPO were ₹6,800.00 million. Revised offer expenses amounted to ₹378.21 million, resulting in revised net proceeds of ₹6,421.80 million. The filing confirms adherence to SEBI regulations regarding IPO fund utilization.
Key Highlights
- Monitoring Agency Report filed for Q2 2026 IPO proceeds utilization.
- CRISIL Ratings confirms no deviation from IPO objects.
- Gross IPO proceeds were ₹6,800 million.
- Revised net proceeds stand at ₹6,421.80 million.
- Report submitted as per SEBI (ICDR) Regulations.
Price Impact
More from AKUMS